Herantis Pharma: A (Small) Pivot to xCDNF - Redeye
Redeye has an overall positive take on the progress presented at yesterday’s R&D Seminar. We give our view of the way forward for Herantis lead projects addressing Parkinson’s Disease (rhCDNF and HER-096).
ANNONS
Redeye has an overall positive take on the progress presented at yesterday’s R&D Seminar. We give our view of the way forward for Herantis lead projects addressing Parkinson’s Disease (rhCDNF and HER-096).